<DOC>
	<DOCNO>NCT02056080</DOCNO>
	<brief_summary>A retrospective , observational , EPA , multicenter study evaluate Clinical Benefit Trastuzumab Combination With Lapatinib Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib January 2005 December 2011</brief_summary>
	<brief_title>Clinical Benefit Treatment With Trastuzumab Combination With Lapatinib Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed diagnosis metastatic breast cancer HER2positive phenotype ( confirm IHC 3 + FISH positive ) Older 18 year Progressed least one prior treatment line MBC trastuzumab / lapatinib , either monotherapy combination chemotherapy hormonal therapy scheme Having patient 's complete medical history contains line antiHER2 therapy treatment Being patient initiate combination trastuzumab lapatinib January 2005 December 2011 Inform patient get signature inform consent Not phenotypic classification tumor IHC FISH test HER2 Being patient HER2negative phenotype ( FISH negative IHC range [ 02 + ] without FISH ) Being patient receive trastuzumab and/or lapatinib treatment ( TL ) combination chemotherapy Being patient , since January 2012 , begin TL therapy metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Breast Neoplasm</keyword>
	<keyword>Receptor , HER2</keyword>
	<keyword>Antineoplastic agent</keyword>
	<keyword>Antibodies , monoclonal</keyword>
	<keyword>Trastuzumab , Lapatinib</keyword>
	<keyword>Protein kinase inhibitor</keyword>
	<keyword>quinazolines</keyword>
</DOC>